Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Agenus stock | $5.13

Learn how to easily invest in Agenus stock.

Agenus Inc is a biotechnology business based in the US. Agenus shares (AGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Agenus employs 359 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Agenus

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AGEN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Agenus stock price (NASDAQ: AGEN)

Use our graph to track the performance of AGEN stocks over time.

Agenus shares at a glance

Information last updated 2021-10-16.
Latest market close$5.13
52-week range$2.50 - $6.79
50-day moving average $5.83
200-day moving average $4.83
Wall St. target price$10.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.13

Buy Agenus shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Agenus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Agenus price performance over time

Historical closes compared with the close of $5.13 from 2021-10-21

1 week (2021-10-14) -6.73%
1 month (2021-09-18) N/A
3 months (2021-07-22) -8.06%
6 months (2021-04-22) 75.68%
1 year (2020-10-22) 25.74%
2 years (2019-10-22) 106.85%
3 years (2018-10-22) 183.43%
5 years (2016-10-21) 5.75

Agenus financials

Revenue TTM $68.5 million
Gross profit TTM $-56,796,000
Return on assets TTM -50.33%
Return on equity TTM 0%
Profit margin 0%
Book value $-1.15
Market capitalisation $1.2 billion

TTM: trailing 12 months

Shorting Agenus shares

There are currently 21.3 million Agenus shares held short by investors – that's known as Agenus's "short interest". This figure is 0.4% down from 21.4 million last month.

There are a few different ways that this level of interest in shorting Agenus shares can be evaluated.

Agenus's "short interest ratio" (SIR)

Agenus's "short interest ratio" (SIR) is the quantity of Agenus shares currently shorted divided by the average quantity of Agenus shares traded daily (recently around 4.2 million). Agenus's SIR currently stands at 5.02. In other words for every 100,000 Agenus shares traded daily on the market, roughly 5020 shares are currently held short.

However Agenus's short interest can also be evaluated against the total number of Agenus shares, or, against the total number of tradable Agenus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Agenus's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Agenus shares in existence, roughly 90 shares are currently held short) or 0.1045% of the tradable shares (for every 100,000 tradable Agenus shares, roughly 105 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Agenus.

Find out more about how you can short Agenus stock.

Agenus share dividends

We're not expecting Agenus to pay a dividend over the next 12 months.

Have Agenus's shares ever split?

Agenus's shares were split on a 1:6 basis on 2 October 2011. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Agenus shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Agenus shares which in turn could have impacted Agenus's share price.

Agenus share price volatility

Over the last 12 months, Agenus's shares have ranged in value from as little as $2.5 up to $6.79. A popular way to gauge a stock's volatility is its "beta".

AGEN.US volatility(beta: 1.4)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agenus's is 1.3968. This would suggest that Agenus's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Agenus overview

Agenus Inc. , a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that is in Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial for dose escalation study; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody to deplete regulatory T cells, which is in a Phase 1 clinical trial; AGEN-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, an anti-TIGIT monospecific antibody. In addition, it develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4, as well as AGENT 797, an iNKT cells that is in Phase 1 clinical trial for the treatment of COVID-19-related pneumonia; and in preclinical stage to treat multiple myeloma/B cell malignancies and solid tumors. The company has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc.

Frequently asked questions

What percentage of Agenus is owned by insiders or institutions?
Currently 12.801% of Agenus shares are held by insiders and 50.464% by institutions.
How many people work for Agenus?
Latest data suggests 359 work at Agenus.
When does the fiscal year end for Agenus?
Agenus's fiscal year ends in December.
Where is Agenus based?
Agenus's address is: 3 Forbes Road, Lexington, MA, United States, 02421-7305
What is Agenus's ISIN number?
Agenus's international securities identification number is: US00847G7051
What is Agenus's CUSIP number?
Agenus's Committee on Uniform Securities Identification Procedures number is: 00847G101

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site